UCB Obtains FDA Approval for Treatment of Plaque Psoriasis After Regulatory Setbacks | BioSpace
Pictured: A woman scratches skin lesions on her elbow/iStock, helivideo The FDA on Wednesday approved UCB’s bimekizumab for the treatment of adults with moderate to severe plaque psoriasis. The treatment will be sold under the Bimzelx brand. Bimzelx is a humanized IgG1 monoclonal antibody that acts by targeting IL-17A and IL-17F, two central players in …